Generated: April 25, 2017
|Title:||Treatment of human viral infections|
|Abstract:||Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose. Additionally, there is disclosed the treatment of Kaposi's sarcoma with 3'-azido-3'-deoxythymidine (AZT) and the synergistic activity in the treatment of humans infected with HTLV-III of AZT and interferon as well as AZT and acyclovir and AZT and 2-amino-9-(2-hydroxyethoxymethyl)purine or an ester thereof.|
|Inventor(s):||Rideout; Janet Litster (Raleigh, NC), Barry; David Walter (Chapel Hill, NC), Lehrman; Sandra Nusinoff (Durham, NC), St. Clair; Martha Heider (Durham, NC), Furman; Phillip Allen (Durham, NC)|
|Assignee:||Glaxo Wellcome Inc. (Research Triangle Park, NC)|
|Filing Date:||Aug 21, 1986|
|Claims:||1. A method of treating a human being who has been diagnosed as being infected with HTLV-III comprising the administration of a non-toxic, effective amount of a combination of 3'-azido-3'-deoxythymidine or its 5'-mono-, 5'-di-, or 5'-triphosphate, or a pharmaceutically acceptable salt thereof, and the compound of formula V. ##STR5## where R is H or ##STR6## wherein R.sup.0 is H, C.sub.1-16 alkyl and physiologically acceptable acid addition salts thereof. |
2. The method of claim 1 in which the combination is 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof and 2-amino-9-(2-hydroxyethoxymethyl)purine or a pharmaceutically acceptable acid addition salt thereof.
3. The method of claim 1 in which R is ##STR7## and R.sup.0 is C.sub.1-6 alkyl or hydrogen and the compound of formula V or salt thereof is in combination with the 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable salt thereof.
4. A method of treating a human being who has been diagnosed as being infected with HTLV-III comprising the administration of 3'-azido-3'-deoxythymidine and 2-amino-9- (2-hydroxyethoxymethyl) purine to said human being.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.